Atea Pharmaceuticals (AVIR) vs Editas Medicine (EDIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Editas Medicine (EDIT) over the past year, gaining 66.3% versus a loss of 30.0%. Over five years, AVIR leads with a -86.9% price change compared with -92.8% for EDIT. Editas Medicine is the larger company by market cap ($436.2 million vs $413.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | EDIT |
|---|---|---|
| Share price | $5.16 | $2.84 |
| Market cap | $413.46M | $436.17M |
| 1-day change | +2.89% | +3.27% |
| YTD return | +44.40% | +34.15% |
| 1-year return | +66.29% | -30.03% |
| 5-year return | -86.88% | -92.77% |
| EPS (TTM) | $-2.09 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $4.33 |
| 52-week low | $2.87 | $1.66 |
| Distance from 52-week high | -20.08% | -34.41% |
| Analyst consensus | none | buy |
| Avg. price target upside | +82.74% | +107.75% |
| Average volume | 298.38K | 2.47M |
| Shares outstanding | 80.20M | 153.58M |
| Employees | 55 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed EDIT by 96.3 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
AVIR vs EDIT FAQ
Which is bigger, Atea Pharmaceuticals or Editas Medicine?
Editas Medicine (EDIT) is larger, with a market capitalization of $436.17M compared with $413.46M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, AVIR or EDIT?
AVIR returned +66.29% over the past 12 months, compared with -30.03% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Editas Medicine in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Atea Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Editas Medicine.